Kura spins off $50M diabetes biotech with Lilly's backing

Diabetes drugs today mostly manage blood sugar — insulin, metformin, the GLP-1 shots everyone's heard of. None of them fix the underlying problem. On Sept. 9, Kura Oncology spun off a new company called Caspian Therapeutics. It launched with $50 million to chase something different. The new drug blocks a protein called menin. Caspian says it could change how diabetes progresses, not just treat its symptoms.

Eli Lilly's involvement is the real signal here. Lilly already sells some of the best-known diabetes treatments in the world. Now it's betting money on a completely different approach, through a company it doesn't fully control. That's Lilly covering its bases, not giving up on its own drugs. If menin inhibition works, Lilly gets a stake in what might replace its own bestsellers. That beats getting blindsided by a smaller rival later. The catch is that none of this has been tried in a person yet. Caspian is still at the stage of cells and animals, not patients.

Keep reading — what to watch

Will menin inhibition actually work in people, not just lab dishes? Caspian is presenting its first public data at a medical conference on Sept. 29. That will be the first real test of whether this approach is more than a theory. Until then, this is a bet on an idea, not a proven treatment.